

# Focus session: FMR and low risk AS – The debate goes on

Moderated by T Walther, Frankfurt | Friday 9th October | 14:45–18:15 | Auditorium

Focus  
session

This session discusses the pros and cons of surgical and transcatheter therapy for valvular heart disease. The session is split in two, with the first half focusing on the treatment of functional mitral regurgitation and the second focusing on treatment of aortic stenosis.

## Presentations

- 14:45 An integrative approach to FMR: measure the right thing– treat the right patient! | T Doenst
- 15:00 Functional MR: GDMT and device therapy as first line treatment! | N Dumonteil
- 15:15 Functional MR: Percutaneous edge-to-edge repair as first line treatment! | U Schäfer
- 15:30 Functional MR: Percutaneous edge-to-edge repair only for the inoperable? | M De Bonis
- 15:45 Functional MR: Transcatheter mitral valve replacement will replace everything else! | T Modine
- 16:00 Moderated discussion
- 16:15 Break
- 16:30 Aortic stenosis and low or intermediate risk: TAVI is the winner! | N Dumonteil
- 16:45 Aortic stenosis and low or intermediate risk: SAVR still rules! | M Borger
- 17:00 Managing complications during TAVI – lessons learned | D Holzhey
- 17:15 Fracturing and leaflet laceration – tricks and tips for complicated VinV | D Dvir
- 17:30 Any limits for TAVI in bicuspid AS? | A Unbehaun
- 17:45 Alternative TAVI concepts | J Scherman

[Click here for more information on the EACTS 2020 scientific programme.](#)

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. NP--EU-0150 V1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • [edwards.com](http://edwards.com)



Edwards